2023
Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
Ellingson M, Sheikha H, Nyhan K, Oliveira C, Niccolai L. Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review. Human Vaccines & Immunotherapeutics 2023, 19: 2239085. PMID: 37529935, PMCID: PMC10399474, DOI: 10.1080/21645515.2023.2239085.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSystematic reviewHuman Papillomavirus Vaccine EffectivenessVaccine-type HPV infectionYounger ageHigh vaccine effectivenessHuman papillomavirus vaccineVaccine effectiveness studiesYounger age groupsAdolescents ages 15Adolescents ages 9HPV infectionHPV vaccineVaccine initiationPapillomavirus vaccineTime vaccinationAnogenital wartsCervical abnormalitiesCervical cancerDisease outcomeAge groupsOlder ageEffectiveness studiesAge 15Age
2022
Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
Oliveira CR, Shapiro ED, Weinberger DM. Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness. Clinical Epidemiology 2022, 14: 1167-1175. PMID: 36281232, PMCID: PMC9587703, DOI: 10.2147/clep.s378039.Peer-Reviewed Original ResearchVaccine effectiveness studiesCase-control studyConfidence intervalsModel uncertaintyYears of ageBayesian model averaging frameworkResidents of ConnecticutModel selection methodsLyme vaccineVaccine effectivenessVE estimatesPotential confoundersImmunization historyHealthy controlsMedical recordsMultivariable modelingBayesian model averagingPerformance of BMANew vaccinesReal-world settingEffectiveness studiesLyme diseaseBMA frameworkParameter estimationControl of confounding
2019
Human papillomavirus vaccination and anogenital warts
Yakely AE, Avni-Singer L, Oliveira CR, Niccolai LM. Human papillomavirus vaccination and anogenital warts. Sexually Transmitted Diseases 2019, Publish Ahead of Print: &na;. PMID: 30461595, PMCID: PMC6640846, DOI: 10.1097/olq.0000000000000948.Peer-Reviewed Original ResearchConceptsAnogenital wartsAge 25 yearsHPV vaccineEffectiveness studiesHPV vaccine impactHuman papillomavirus vaccinationPre-vaccine eraMale vaccinationPapillomavirus vaccinationVaccination historyVaccine impactVaccine introductionFemale vaccinationEmbase databasesVaccination programEligible studiesExclusion criteriaLower riskVaccineVaccinationWartsPrevention potentialReal-world benefitsFemalesUnited States